Analysts Set Sage Therapeutics, Inc. (SAGE) Price Target at $89.00

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have been assigned an average rating of “Buy” from the sixteen analysts that are presently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $89.00.

A number of research firms have commented on SAGE. Needham & Company LLC reduced their price objective on shares of Sage Therapeutics from $95.00 to $86.00 and set a “buy” rating for the company in a research note on Wednesday, September 13th. Royal Bank of Canada began coverage on shares of Sage Therapeutics in a research note on Thursday, September 14th. They set an “outperform” rating and a $117.00 price objective for the company. Chardan Capital reaffirmed a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday, September 13th. HC Wainwright upped their price objective on shares of Sage Therapeutics to $86.00 and gave the company a “neutral” rating in a research note on Friday, August 4th. Finally, BidaskClub lowered shares of Sage Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 23rd.

WARNING: “Analysts Set Sage Therapeutics, Inc. (SAGE) Price Target at $89.00” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://ledgergazette.com/2017/09/19/analysts-set-sage-therapeutics-inc-sage-price-target-at-89-00.html.

A number of institutional investors and hedge funds have recently modified their holdings of SAGE. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Sage Therapeutics by 11.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 138 shares in the last quarter. Turner Investments LLC bought a new position in Sage Therapeutics during the second quarter valued at approximately $159,000. Dubuque Bank & Trust Co. bought a new position in Sage Therapeutics during the second quarter valued at approximately $167,000. Canada Pension Plan Investment Board bought a new position in Sage Therapeutics during the second quarter valued at approximately $175,000. Finally, Ameritas Investment Partners Inc. bought a new position in Sage Therapeutics during the first quarter valued at approximately $180,000.

Sage Therapeutics (SAGE) traded down 2.07% during trading on Friday, hitting $61.40. 723,168 shares of the stock were exchanged. Sage Therapeutics has a 12-month low of $38.30 and a 12-month high of $90.80. The firm’s market cap is $2.30 billion. The stock’s 50-day moving average price is $80.79 and its 200-day moving average price is $74.87.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) EPS for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.25). During the same quarter in the prior year, the firm earned ($1.08) EPS. On average, equities analysts expect that Sage Therapeutics will post ($7.38) EPS for the current year.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply